WATERS CORP /DE/ (WAT) Stock
WAT has an Alpha Score of 41 out of 100 (weak), computed on Oct 30, 2026 from 3 of 4 sub-scores. 10 members of Congress disclosed 24 trades in WAT since 2019: 12 purchases and 10 sales, most recently Kevin Hern (sale, Aug 13, 2026). 7 of the hedge funds AlphaScala tracks reported WAT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Fundsmith's at $852.70M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 263.8 and its net margin 3.6% (key statistics as of Oct 22, 2026).
What is WAT's Alpha Score?
How it works →Alpha Score of 41 reflects weak overall profile with strong momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded WATERS CORP /DE/ (WAT)?
Most recent: Kevin Hern (sale, Aug 13, 2026); records start Jun 27, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-08-13 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-18 | purchase | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2026-03-10 | partial sale | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2026-02-13 | partial sale | $1k – $15k |
| Debbie Dingell D-MI · House | 2026-02-10 | exchange | $1k – $15k |
| Kevin Hern R-OK · House | 2026-02-09 | exchange | $1k – $15k |
| Julia Letlow R-LA · House | 2025-12-08 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-09-30 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded WAT, with filing lags →Which hedge funds own WAT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Fundsmith Terry Smith | 2.27M | $852.70M | -29% |
| Viking Global Investors Andreas Halvorsen | 1.66M | $623.37M | +32% |
| D.E. Shaw David Shaw | 949K | $355.78M | -7% |
| Millennium Management Israel Englander | 895K | $335.53M | +383% |
| Marshall Wace | 581K | $218.02M | +156% |
| Point72 Steve Cohen | 444K | $166.60M | +25% |
| Citadel Ken Griffin | 136K | $50.89M | -35% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are WATERS CORP /DE/ insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 6, 26 | Kuebler Christopher A | Director | SELL | 3.6K | $1.4M |
| Mar 16, 26 | Jiang Wei | Director | BUY | 500 | $145K |
| Mar 6, 26 | Fearon Richard H | Director | BUY | 1.0K | $306K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are WAT's key statistics?
Key statistics as of Oct 22, 2026
How does WAT's valuation compare with the Healthcare sector?
| Metric | WAT | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 263.8 | 27.1 | 97 |
| Net margin | 3.58% | 5.48% | 139 |
| Return on equity | 1.88% | 6.84% | 158 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
WAT price chart
Powered by TradingViewWhat does WATERS CORP /DE/ do?
Waters Corporation is a leading provider of analytical instruments and software solutions for scientific research and quality control in laboratory environments worldwide. The company specializes in liquid chromatography, mass spectrometry, and thermal analysis technologies that deliver essential molecular and physical property information to support product development and quality assurance. Waters serves three primary markets: biopharmaceutical firms utilizing its instruments for drug development and regulatory compliance, industrial clients across various manufacturing sectors, and academic and government research institutions. The company's analytical instruments are considered gold standards in their applications, particularly in liquid chromatography-mass spectrometry for biopharmaceutical research. In early 2026, Waters is undergoing a significant merger with BD's life science and diagnostics business, which will expand its portfolio and market reach into diagnostics and discovery-related life science tools, fundamentally broadening the company's service offerings and customer concentrations.